Slide 1: Q2 2026 Earnings Call Presentation
Q2 2026 Earnings Call Presentation August │ 2026 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Auna S.A. (“Auna” or the “Company”) solely for use at this presentation. This presentation contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known a
Slide 3: Today's Speakers
Today’s Speakers +30 +20 +25 Jesus Zamora Gisele Remy Lorenzo Massart Executive Chairman of the Board and Chief Financial Officer and Executive Vice President, Strategy and President Executive Vice President Equity Capital Markets • Member of the Board since 2008 and President • Chief Financial Offi
Slide 4: 2Q'26 Highlights
2Q’26 Highlights Consolidated Revenues1 +9% FXN YoY vs 2Q’25 with revenue increases across all business segments. “The second Adjusted EBITDA1,2 -9% FXN YoY with 18.4% margin, -3.7p.p. vs 2Q’25; +3% FXN QoQ with quarter flat margin growth. demonstrated clear progress in Mexico’s volume recovery acce
Slide 5: Strong top line across all segments and robust cash flow generation
Strong top line across all segments and robust cash flow generation Consolidated Adjusted EBITDA impacted by service mix, temporary cost pressures and billing penalties Consolidated 2Q26 Revenue (S/) Adjusted EBITDA(1) (S/) 1,238Mn 227 Mn +13% YoY -6% YoY +9% FXN YoY -9% FXN YoY Healthcare Services
Slide 6: Q2 2026 Results by Segment
Q2 2026 Results by Segment qauna
Slide 7: Healthcare Services Mexico grows revenues YoY
Healthcare Services Mexico grows revenues YoY. QoQ revenues grew from 2026 initiatives executed in the network, including doctor onboarding, tier upgrades and oncology volumes. Revenue and Adjusted EBITDA increased sequentially by 5% and 3%, respectively. External Revenue1 (S/ Mn, %) Adj. EBITDA and
Slide 8: Peru revenue growth from higher Oncosalud pricing and B2B memberships
Peru revenue growth from higher Oncosalud pricing and B2B memberships and HC network focus on high complexity. Adj. EBITDA negatively impacted by accepted penalties from reconciliation of prior years’ receivables. External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 43 % of LTM Revenues
Slide 9: Colombia expands risk sharing agreements and improves payment terms
Colombia expands risk sharing agreements (“PGPs”) and improves payment terms. YoY Adjusted EBITDA impacted by higher variable costs and statutory wage increases, which we expect to be offset by price adjustments in the 2H as we continue to stabilize PGPs. External Revenue1 (S/ Mn, %) Adj. EBITDA and
Slide 10: Q2 2026 Consolidated Results
Q2 2026 Consolidated Results 10
Slide 11: Strategic initiatives executed across all segments result in sustained revenue growth
Strategic initiatives executed across all segments result in sustained revenue growth ▪ Mexico increased YoY volumes: +6% in surgery and +86% in oncology with operating utilization of 49.9%, +6.0 p.p. ▪ Peru adds 7,000 memberships through B2B; the HC network increased high complexity surgery volumes
Slide 12: Consolidated Adjusted EBITDA reflects temporary margin pressures
Consolidated Adjusted EBITDA reflects temporary margin pressures from service mix, pharmacy and payroll costs, as well as, the impact of accepted penalties from reconciliation of prior years’ receivables. ▪ PEN/MXN depreciation of 5% and PEN/COP depreciation of 9% YoY. Adjusted EBITDA1 Bridge 2Q’26
Slide 13: Adjusted Net Income of S/40 million
Adjusted Net Income of S/40 million, on lower FX gain and operating profit, partially offset by lower net interest expenses and improved income tax efficiencies. ▪ Lower non-cash FX gains mainly due to the depreciation of the Peruvian Sol below the protection range of Auna’s new hedging structure im
Slide 14: Free Cash Flow generation expands 181% versus 2Q25
Free Cash Flow generation expands 181% versus 2Q25 off the back of working capital discipline and supplier financing initiatives. EoP cash grows 43% versus year-end 2025. ▪ Free cash flow includes Maintenance CapEx of S/65 million, or 3% of revenues ▪ On track to achieve 3.0x medium term leverage ta
Slide 15: Leverage ratio improved QoQ on lower gross debt and improved EoP cash
Leverage ratio improved QoQ on lower gross debt and improved EoP cash Debt Structure Highlights Debt by Type (%) Debt by Currency (%) ✓ Committed to achieving 3.0x Leverage Ratio target. Consolidated Debt: S/3,730 ✓ Gross Debt decreased by PEN 43 million on a FX-neutral basis as of 2Q26. However, Te
Slide 16: We are reaffirming our full-year 2026 revenue guidance
Peru continues demonstrating the success of Auna’s vertically integrated model at scale. The healthcare services network will continue prioritizing high-complexity surgical “We are procedures, while Oncosalud profitability should improve as onboarding from new B2B accounts normalizes. Strategic, ass
Slide 17: Q&A
Q&A qund
Slide 18: Exhibits
Exhibits qund
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Jun-26 Δ Jun-26 Jun-26 Δ Jun-26 Jun-26 Dec-25 Jun-26 Dec-25 (USD) vs Dec-25 (USD) vs Dec-25 Assets Liabilities Current assets Current liabilities Cash and cash equivalents 140 478 335 142
Slide 20: Consolidated Statement of Income (1/2)
Consolidated Statement of Income (1/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 2Q'26 Δ 2Q'26 vs Δ YTD 26 vs 2Q'26 YTD 26 (USD) 2Q'25 YTD 25 Revenue Healthcare Services Mexico 88 300 579 10% 12% Healthcare Services Colombia 125 426 824 23% 20% - Healthcar
Slide 21: Consolidated Statement of Income (2/2)
Consolidated Statement of Income (2/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 2Q'26 Δ 2Q'26 vs Δ YTD 26 vs 2Q'26 YTD 26 (USD) 2Q'25 YTD 25 Share of profit of equity accounted investees 1 2 5 3% -3% Profit (loss) before tax 17 59 76 -55% -61% Income tax
Slide 22: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) YTD 26 Δ YTD 26 YTD 26 Δ YTD 26 YTD 26 YTD 25 YTD 26 YTD 25 (USD) vs YTD 25 (USD) vs YTD 25 Cash flows from operating activities Cash flows from investing activities (Loss) profit f
Slide 23: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre- operating expenses for
Slide 24: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued)
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) For the three months ended June 30, 2026 Healthcare Healthcare Healthcare Consolidated Oncosalud Holding and Services Services Services Reportab
Slide 25: Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued)
Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Year to date June 30, 2026 Healthcare Healthcare Healthcare Consolidated Oncosalud Holding and Services Services Services Reportable Peru elimin
Slide 26: Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru Segment Adjusted EBITDA plus Oncosalud Peru Segment Ad
Slide 27: Adjusted Net Income reconciliation
Adjusted Net Income reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below. 2Q'26 2Q'26 2Q'25 YTD 26 YTD 25 (USD) Net Income (Loss) 10 33 84 42 122 (a)
Slide 28: Free Cash Flow
Free Cash Flow (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investing activities. Jun-25 Jun-26 Cash generated from operating activities 351 507 (-) Income t ax
Slide 29: Adjusted Basic and Diluted Earnings per Share
Adjusted Basic and Diluted Earnings per Share (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Inc
Slide 30: Net Debt reconciliation
Net Debt reconciliation (Figures in millions of Soles, unless expressed otherwise) Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents. Jun-25 Dec-25 Jun-26 (+) Loans and borrowings 3,574 3,533 3,606 Short t erm debt 598 316 399 Long t erm debt 2,976 3,216 3,207 (+) Lease L
Slide 31: Leverage Ratio reconciliation
Leverage Ratio reconciliation (Figures in millions of Soles, unless expressed otherwise) Leverage Ratio: is calculated as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted
Slide 32: Key Operational Metrics – Oncosalud Peru & Healthcare Services
Key Operational Metrics – Oncosalud Peru & Healthcare Services 1) As of period end. 2) As reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans. Includes active plan members and inactive members. Inactive members are defined as those plan members that h
Slide 33: Trends in Key Financial Metrics
Trends in Key Financial Metrics (Figures in millions of Soles, unless expressed otherwise) 2Q'24 3Q'24 4Q'24 1Q'25 2Q'25 3Q'25 4Q'25 1Q'26 2Q'26 Revenue Oncosalud Peru 269 273 276 281 286 294 304 314 317 Healthcare Services Peru 255 255 245 263 269 279 273 281 296 Healthcare Services Colombia 378 36
Slide 34: Investor Relations
Investor Relations contact@aunainvestors.com www.aunainvestors.com 34